Chrysin (Flavone · Anxiolytic · Aromatase Inhibition)
| Compound | Chrysin |
| Chemical class | Polyphenol — Flavone (5,7-Dihydroxyflavone) |
| CAS | 480-40-0 |
| Primary source | Propolis, Passiflora caerulea (blue passionflower), Oroxylum indicum |
| Key applications | Anxiolytic (GABA-A), anti-inflammatory, aromatase inhibition |
| Claim strength | Moderate |
| Typical form | Chrysin isolate powder; propolis extract |
Name origin: From Greek chrysos (gold) — reflecting the yellow colour of the crystals. Chrysin is the simplest flavone commonly encountered in botanical commerce, with hydroxyl groups only at C-5 and C-7. Traditional use: Propolis (bee glue), a rich natural source of chrysin, has been used across Mediterranean, Eastern European, and Middle Eastern traditions as an antimicrobial and wound-healing agent. Passiflora species containing chrysin have traditional use as nervines. Research trajectory: Chrysin attracted significant interest as a GABA-A modulator (anxiolytic), a natural aromatase inhibitor (bodybuilding and hormone contexts), and an anti-inflammatory agent. Bioavailability challenges have moderated initial enthusiasm; nanoformulated chrysin is an active area. Commercial source: Herbuno supplies chrysin powder directly.
Evidence for Chrysin Applications
Anxiolytic activity via GABA-A modulation: Chrysin binds to the benzodiazepine site of GABA-A receptors in vitro and in animal behavioural studies, producing anxiolytic effects comparable to low-dose benzodiazepines in rodent models. Human clinical evidence is limited — poor oral bioavailability (<1% in standard form) is a key barrier to clinical translation. Nanoencapsulated chrysin shows improved bioavailability in animal studies. Claim strength: Moderate (strong mechanism; limited human data due to bioavailability).
Aromatase inhibition: Chrysin is a natural aromatase (CYP19A1) inhibitor with IC50 in the low micromolar range in vitro. This mechanism is relevant to testosterone optimisation and oestrogen management formulations. Human bioavailability remains the limiting factor; controlled aromatase inhibition studies in humans are absent. Claim strength: Moderate (mechanism established; clinical outcome unproven).
Anti-inflammatory and antioxidant: Chrysin suppresses NF-κB, reduces TNF-α and IL-6 in macrophage models, and demonstrates Nrf2 activation. In vivo anti-inflammatory efficacy is documented in animal models of colitis, lung injury, and diabetic nephropathy. Claim strength: Moderate.
Dosage & Formulator Specification
Standard chrysin powder (≥98% HPLC) is commercially available from Herbuno. Typical doses used in human and animal studies: 500–3000 mg/day. However, bioavailability of standard chrysin powder is very low (<1%) due to poor dissolution and extensive phase II metabolism. Published doses should be interpreted with this limitation in mind.
Bioavailability-enhanced delivery strategies: phospholipid complexation (chrysin-phytosome, 1:2 ratio with soy phosphatidylcholine) improves absorption 3–5-fold in animal studies; piperine co-administration (20 mg piperine per 500 mg chrysin) has been studied in humans and shown modestly improved plasma levels. Nanoparticle encapsulation (PLGA, chitosan) is the most effective in preclinical data but is not yet commercially scaled for supplements.
For aromatase inhibition contexts, a chrysin-phytosome formulation (200–500 mg chrysin equivalent) co-administered with meals (high-fat context improves passive absorption) is the most rational current approach. Formulators should be transparent about the bioavailability limitation in technical documentation.
Frequently Asked Questions — Chrysin
Why did chrysin underperform as a testosterone booster in early supplement marketing?
Early marketing overstated chrysin’s aromatase-inhibiting potential based on in vitro IC50 values, without accounting for its very low oral bioavailability. Controlled human studies using standard chrysin powder showed no significant effect on serum oestrogen or testosterone. The mechanism is valid; the delivery has been the limiting factor.
Does piperine meaningfully improve chrysin bioavailability?
A small human pharmacokinetic study found piperine co-administration increased chrysin plasma levels, but the absolute bioavailability remained low. Piperine’s CYP and P-gp inhibition may also alter the metabolism of other co-formulated compounds, which must be considered for complex supplement formulas.
Is chrysin from propolis equivalent to synthetic chrysin?
Propolis extracts contain chrysin alongside other flavones (galangin, pinocembrin, kaempferide) and phenolic acids. These co-constituents may contribute synergistically to propolis bioactivity. Isolated synthetic or plant-derived chrysin lacks these co-constituents; the two are not functionally equivalent in formulation.
What regulatory status does chrysin carry?
Chrysin has no approved health claim in EU or US regulatory frameworks. It is marketed as a botanical ingredient in supplements in most markets. Novel Food status is not required in the US (marketed before 1994 in some formats); EU Novel Food assessment may apply depending on source and extraction method.
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery